Extendicare (TSE:EXE – Get Free Report) has been given a C$34.50 target price by Desjardins in a research report issued on Wednesday,BayStreet.CA reports. The brokerage currently has a “buy” rating on the stock. Desjardins’ target price indicates a potential upside of 20.17% from the company’s previous close.
EXE has been the topic of a number of other reports. TD Securities upgraded shares of Extendicare from a “hold” rating to a “buy” rating and lifted their price objective for the company from C$19.00 to C$32.00 in a report on Monday, April 6th. Canadian Imperial Bank of Commerce increased their target price on shares of Extendicare from C$22.00 to C$32.00 in a report on Thursday, April 2nd. BMO Capital Markets raised their target price on shares of Extendicare from C$24.00 to C$30.00 in a research report on Monday, March 2nd. Finally, National Bank Financial lifted their price target on shares of Extendicare from C$24.50 to C$29.00 and gave the company an “outperform” rating in a research note on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of C$29.38.
Read Our Latest Report on Extendicare
Extendicare Stock Up 1.3%
Extendicare (TSE:EXE – Get Free Report) last released its earnings results on Thursday, February 26th. The company reported C$0.29 EPS for the quarter. Extendicare had a return on equity of 47.65% and a net margin of 5.82%.The firm had revenue of C$462.03 million for the quarter. On average, sell-side analysts expect that Extendicare will post 0.6134729 EPS for the current fiscal year.
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
See Also
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
